Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockade

ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBCПодробнее

APHINITY: 6-year follow-up results of dual HER2 blockade in HER2+ breast cancerПодробнее

HER2-E pCR with anti-HER2-based neoadjuvant therapiesПодробнее

Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast CancerПодробнее

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...Подробнее

Dual HER2 Blockade in Early Breast CancerПодробнее

Dual HER2 blockade in patients with HER2-positive breast cancer after pCRПодробнее

Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancerПодробнее

Phase II ADAPT Trial in Patients With HER2+ and HR+ Early Breast CancerПодробнее

Dr. Murthy on Dual HER2 Blockade in HER2+ Breast CancerПодробнее

Gluz: Final Analysis of WSG-ADAPT HER2+/HR+Подробнее

Advancing HER2+ GC treatmentПодробнее

Dr. Gradishar Discusses Dual HER2-Targeting in Breast CancerПодробнее

CALGB 40601 Alliance: impact of dual HER2 targeting on pCRПодробнее

Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast CancerПодробнее

Ado trastuzumab Emtansine A Targeted Therapy for HER2 Positive Breast CancerПодробнее

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast CancerПодробнее

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemoПодробнее

Assessment of short preoperative endocrine therapy in the ADAPT and ADAPTcycle trialsПодробнее